Science & ClimateNovember 20, 20263 min readBy Peter OlaleruEditor

Daraxonrasib Shrinks Tumors in 61% of Pancreatic Cancer Patients, but Only 61 Have Tried It

Early trial shows daraxonrasib combined with chemotherapy shrank tumors in 61% of advanced pancreatic cancer patients, but only 61 patients have tried it.

TweetLinkedIn
Report an issue
A hospital room with a bed and a television, for a story on daraxonrasib shrinking tumors in pancreatic cancer patients.
Photo: Unsplash

An experimental once-a-day pill is producing striking tumor responses in pancreatic cancer, but the most important number may be how few patients have actually tried it.

In a small clinical trial, the oral drug daraxonrasib combined with chemotherapy shrank tumors substantially in 61% of patients with advanced pancreatic cancer, including complete responses in 8% — about one in 12. Median progression-free survival was 12.8 months, compared with roughly six to seven months seen in previous studies of standard chemotherapy. Seventy-seven percent of patients were still alive one year after starting treatment, and 90% of the 61 patients experienced either tumor shrinkage or stable disease.

The results were presented by lead investigator Dr. Brian Wolpin at the 2026 American Society of Clinical Oncology annual meeting in Chicago on May 31, where he received a standing ovation. The drug targets RAS proteins, which regulate cell growth and can become abnormally active in cancer. More than nine in ten pancreatic ductal adenocarcinomas carry mutations in RAS genes, and KRAS is the most common of these mutations, driving over 90% of pancreatic cancer.

One-year survival rate for pancreatic cancer patients

The daraxonrasib trial raised one‑year survival from about 25% to roughly 77%.

0%25%50%75%Daraxonrasib trialDaraxonrasib trialDaraxonrasib trial: 77%77%Current standardCurrent standardCurrent standard: 25%25%

It has received breakthrough designation from the U.S. Food & Drug Administration.

Pancreatic cancer is the third-leading cause of cancer deaths in the U.S., killing nearly 53,000 people each year, and is projected to become the second most deadly cancer in the United States by 2030. Current one-year survival for adults diagnosed with the disease is only about 25%. A therapy that pushes one-year survival to roughly 77% in an early trial represents a potentially meaningful shift for a disease that has been a stubborn foe.

But the results are early-stage and small. The trial enrolled 61 patients.

Sources

TweetLinkedIn

Reader notes

Loading comments...